Our coverage of ASCO 2024 has rounded the final bend, and the finish line is in sight. Today, Josh and Michael examine four studies in the head and neck cancer space. Today's studies include a novel, viral-driven vector that aims to increase the immune response to treatment, potential treatment for the very rare nasal squamous cell cancer, data supporting the treatment of patients with poor prognosis and head and neck patients, and a new, intensive immunotherapy treatment for nasopharyngeal cancer. A wide variety of studies that are sure to satisfy a broad range of palates!

Links to studies discussed in this episode (subscription may be required):

TARGET-HPV: Link

Phase 3 randomized study for evaluation of physician choice Rx versus best supportive care as second-line or beyond therapy in head and neck cancer with poor performance status: Link

KCSG HN18-07: Link

Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial: LinkFor more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.